Alvotech (ALVO) Form 424B5 — Jun 15, 2026
Alvotech filed a preliminary prospectus supplement to offer ordinary shares to the public, concurrent with a private placement to investors in the European Economic Area. BofA Securities, Jefferies, and Evercore ISI are acting as joint book-running managers for the offering, which aims to bolster the company's financial position. The filing follows recent regulatory challenges, including Complete Response Letters (CRLs) from the FDA for AVT05, AVT06, and AVT03 regarding deficiencies at the Reykjavik manufacturing facility. Alvotech has since resubmitted BLAs for AVT05 and AVT06 and announced that the BLA for AVT16 has been accepted for review.
Key figures
- Total Debt
- 1309631000
- Cash Position
- 63832000
- Shares Outstanding
- 312153164
- Closing Price
- 4.17
Price after filing
Close on the filing date to close N calendar days later (from $4.24). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.